Sign in or create an account to add this stock to your watchlist.
About Oxford Immunotec Global (NASDAQ:OXFD)
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780
Debt
Debt-to-Equity Ratio0.38
Current Ratio5.60
Quick Ratio5.04
Price-To-Earnings
Trailing P/E Ratio-10.26
Forward P/E Ratio-14.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$103.08 million
Price / Sales3.50
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book4.53
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-34.13%
Return on Equity-43.51%
Return on Assets-24.49%
Miscellaneous
Employees457
Outstanding Shares25,880,000
Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions
What is Oxford Immunotec Global's stock symbol?
Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its earnings results on Tuesday, May, 1st. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.05. The firm had revenue of $21.37 million for the quarter, compared to analysts' expectations of $20.96 million. Oxford Immunotec Global had a negative return on equity of 43.51% and a negative net margin of 34.13%. The firm's quarterly revenue was down .7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.36) earnings per share. View Oxford Immunotec Global's Earnings History.
When is Oxford Immunotec Global's next earnings date?
What price target have analysts set for OXFD?
4 equities research analysts have issued 12 month price objectives for Oxford Immunotec Global's shares. Their predictions range from $15.00 to $20.00. On average, they expect Oxford Immunotec Global's stock price to reach $18.25 in the next year. View Analyst Ratings for Oxford Immunotec Global.
Who are some of Oxford Immunotec Global's key competitors?
Some companies that are related to Oxford Immunotec Global include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), New England Nuclear (LNTH), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), ARCA biopharma (ABIO), GeneNews (GNWSF) and FluoroPharma Medical (FPMI).
Who are Oxford Immunotec Global's key executives?
Oxford Immunotec Global's management team includes the folowing people:
- Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 44)
- Mr. Richard M. Altieri, CFO and Principal Financial & Accounting Officer (Age 58)
- Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 57)
- Mr. Stefan C. Linn, Chief Operating Officer (Age 53)
- Ms. Karen C. Koski, Head of Strategy & Investor Relations
Has Oxford Immunotec Global been receiving favorable news coverage?
News articles about OXFD stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a daily sentiment score of 0.21 on Accern's scale. They also gave media headlines about the company an impact score of 44.52 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Oxford Immunotec Global's major shareholders?
Oxford Immunotec Global's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (9.54%), BlackRock Inc. (4.49%), Wasatch Advisors Inc. (2.88%), First Light Asset Management LLC (2.42%), Cortina Asset Management LLC (1.98%) and Northern Trust Corp (1.00%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.
Which major investors are selling Oxford Immunotec Global stock?
OXFD stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Cortina Asset Management LLC, Tiverton Asset Management LLC, Millennium Management LLC, Neuburgh Advisers LLC, Flinton Capital Management LLC, C WorldWide Group Holding A S and Northern Trust Corp. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.
Which major investors are buying Oxford Immunotec Global stock?
OXFD stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Redmile Group LLC, BlackRock Inc., Spark Investment Management LLC, Birchview Capital LP, First Light Asset Management LLC, Trexquant Investment LP and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Oxford Immunotec Global.
How do I buy shares of Oxford Immunotec Global?
Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global's stock price today?
One share of OXFD stock can currently be purchased for approximately $13.95.
How big of a company is Oxford Immunotec Global?
Oxford Immunotec Global has a market capitalization of $355.87 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.
How can I contact Oxford Immunotec Global?
Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]
MarketBeat Community Rating for Oxford Immunotec Global (OXFD)
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oxford Immunotec Global (NASDAQ:OXFD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Oxford Immunotec Global in the last 12 months. Their average twelve-month price target is $18.25, suggesting that the stock has a possible upside of 30.82%. The high price target for OXFD is $20.00 and the low price target for OXFD is $15.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.25 | $18.75 | $18.75 | $19.75 |
| Price Target Upside: | 30.82% upside | 62.90% upside | 62.90% upside | 49.39% upside |
Oxford Immunotec Global (NASDAQ:OXFD) Consensus Price Target History
Oxford Immunotec Global (NASDAQ:OXFD) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Oxford Immunotec Global (NASDAQ:OXFD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Oxford Immunotec Global (NASDAQ OXFD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.61%
Institutional Ownership Percentage: 91.62%
Oxford Immunotec Global (NASDAQ OXFD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/1/2018 | Richard A Sandberg | Director | Sell | 3,000 | $12.77 | $38,310.00 | 18,000 |  |
| 2/16/2018 | Richard A Sandberg | Director | Sell | 3,000 | $12.01 | $36,030.00 | | |
| 11/1/2017 | Richard A Sandberg | Director | Sell | 3,000 | $13.35 | $40,050.00 | 17,778 | |
| 10/2/2017 | Peter Wrighton-Smith | CEO | Sell | 55,000 | $16.78 | $922,900.00 | | |
| 9/1/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.82 | $47,460.00 | 18,000 | |
| 8/15/2017 | Peter Edwardson | COO | Sell | 9,739 | $16.14 | $157,187.46 | 92,905 | |
| 8/7/2017 | Peter Edwardson | COO | Sell | 22,371 | $17.70 | $395,966.70 | 102,644 | |
| 7/6/2017 | Peter Wrighton-Smith | CEO | Sell | 27,168 | $15.94 | $433,057.92 | 488,836 | |
| 7/5/2017 | Peter Wrighton-Smith | CEO | Sell | 32,832 | $16.58 | $544,354.56 | 478,106 | |
| 6/28/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $16.06 | $481,800.00 | 491,668 | |
| 6/15/2017 | Elizabeth M Keiley | VP | Sell | 4,085 | $15.01 | $61,315.85 | 25,393 | |
| 5/15/2017 | Peter Edwardson | COO | Sell | 10,000 | $14.66 | $146,600.00 | 125,015 | |
| 5/10/2017 | Richard A Sandberg | Director | Sell | 3,000 | $14.40 | $43,200.00 | 20,174 | |
| 5/9/2017 | Jeff R Schroeder | Insider | Sell | 40,000 | $14.14 | $565,600.00 | 149,544 | |
| 4/3/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $15.43 | $462,900.00 | 491,668 | |
| 4/3/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.47 | $46,410.00 | 17,174 | |
| 3/20/2017 | Elizabeth M Keiley | VP | Sell | 3,000 | $16.05 | $48,150.00 | 25,429 | |
| 2/6/2017 | Peter Wrighton-Smith | CEO | Sell | 25,000 | $13.36 | $334,000.00 | 463,495 | |
| 12/16/2016 | Peter Wrighton-Smith | CEO | Sell | 7,052 | $15.07 | $106,273.64 | 450,366 | |
| 12/5/2016 | Peter Wrighton-Smith | CEO | Sell | 1,140 | $15.00 | $17,100.00 | 444,454 | |
| 12/2/2016 | Peter Wrighton-Smith | CEO | Sell | 61,808 | $15.00 | $927,120.00 | 504,122 | |
| 11/8/2016 | Richard A Sandberg | Director | Sell | 12,000 | $14.17 | $170,040.00 | 31,774 | |
| 11/18/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.48 | $67,400.00 | 32,174 | |
| 11/17/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.00 | $65,000.00 | 37,174 | |
| 6/16/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 41,230 | $14.30 | $589,589.00 | | |
| 6/15/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 1,529 | $14.27 | $21,818.83 | | |
| 6/12/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 31,598 | $14.27 | $450,903.46 | | |
| 6/10/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 24,649 | $14.28 | $351,987.72 | | |
| 6/9/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 13,000 | $14.26 | $185,380.00 | | |
| 6/8/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 2,662 | $14.25 | $37,933.50 | | |
| 6/3/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 36,474 | $14.29 | $521,213.46 | | |
| 6/1/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.14 | $42,420.00 | | |
| 3/23/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 53,415 | $14.49 | $773,983.35 | | |
| 3/19/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 154,319 | $14.65 | $2,260,773.35 | | |
| 1/14/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.00 | $42,000.00 | | |
| 12/5/2014 | Patricia Randall | Director | Sell | 5,000 | $12.06 | $60,300.00 | | |
(Data available from 1/1/2013 forward)
Oxford Immunotec Global (NASDAQ OXFD) News Headlines
| Source: |
|
Oxford Immunotec Global (NASDAQ:OXFD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Oxford Immunotec Global (NASDAQ:OXFD) Income Statement, Balance Sheet and Cash Flow Statement
Oxford Immunotec Global (NASDAQ OXFD) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
